The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Open accessAbstract
BACKGROUND: Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients. METHODS: In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite H-antihistamine therapy (licensed doses). We randomly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omalizumab at doses of 75 mg, 150 mg, or 300 mg or placebo, followed by a 16-week observation period. The primary efficacy outcome was the change from baseline in a weekly itch-severity score (ranging from 0 to 21, with higher scores indicating more severe itching). RESULTS: The baseline weekly itch-severity score was approximately 14 in all four study groups. At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was -5.1±5.6 in the placebo group, -5.9±6.5 in the 75-mg group (P=0.46), -8.1±6.4 in the 150-mg group (P=0.001), and -9.8±6.0 in the 300-mg group (P<0.001). Most prespecified secondary outcomes at week 12 showed similar dose-dependent effects. The frequency of adverse events was similar across groups. The frequency of serious adverse events was low, although the rate was higher in the 300-mg group (6%) than in the placebo group (3%) or in either the 75-mg or 150-mg group (1% for each). CONCLUSIONS: Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamines. (Funded by Genentech and Novartis Pharma; ClinicalTrials.gov number, NCT01292473.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Maurer, M., Weller, K., Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P. J., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02496.x · Cited by 843
Self-citationMacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A., Grattan, C. E. H., Kapp, A., Merk, H. F., Rogala, B., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02179.x · Cited by 731
Self-citationEAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M., Merk, H. F., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02178.x · Cited by 527
Self-citationThe impact of chronic urticaria on the quality of life
O'DONNELL, B. F., LAWLOR, F., SIMPSON, J., MORGAN, M., & GREAVES, M. W. (1997) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1997.tb14895.x · Cited by 465
Omalizumab-induced reductions in mast cell FcεRI expression and function
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A., & Saini, S. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.032 · Cited by 456
Self-citationSaini, S., Rosen, K. E., Hsieh, H.-J., Wong, D. A., Conner, E., Kaplan, A., Spector, S., & Maurer, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.010 · Cited by 398
Self-citationChronic Urticaria and Angioedema
Kaplan, A. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011186 · Cited by 375
Self-citationGreaves, M. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322608 · Cited by 370
Cited by
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer‐Weber, B., Bernstein, J. A., Bindslev‐Jensen, C., Brzoza, Z., Buense Bedrikow, R., et al. (2018) · Allergy · doi:10.1111/all.13397 · Cited by 1,445
Self-citationZuberbier, T., Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., Ballmer‐Weber, B., Bangert, C., Ben‐Shoshan, M., Bernstein, J. A., et al. (2022) · Allergy · doi:10.1111/all.15090 · Cited by 1,263
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
The diagnosis and management of acute and chronic urticaria: 2014 update
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., Sheikh, J., Weldon, D., Zuraw, B., Bernstein, D. I., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.036 · Cited by 682
Kaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.013 · Cited by 573
Self-citationMast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Saini, S. S., Bindslev-Jensen, C., Maurer, M., Grob, J.-J., Bülbül Baskan, E., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.306 · Cited by 471
Self-citationEuropean S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
Kolkhir, P., Giménez-Arnau, A. M., Kulthanan, K., Peter, J., Metz, M., & Maurer, M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00389-z · Cited by 382
Self-citationBSACI guideline for the management of chronic urticaria and angioedema
Powell, R. J., Leech, S. C., Till, S., Huber, P. A. J., Nasser, S. M., & Clark, A. T. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12494 · Cited by 377
The global burden of chronic urticaria for the patient and society*
Gonçalo, M., Gimenéz‐Arnau, A., Al‐Ahmad, M., Ben‐Shoshan, M., Bernstein, J. A., Ensina, L. F., Fomina, D., Galvàn, C. A., Godse, K., Grattan, C., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19561 · Cited by 357
Self-citationFajt, M. L., & Wenzel, S. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1871 · Cited by 353
Why we scratch an itch: the molecules, cells and circuits of itch
Bautista, D. M., Wilson, S. R., & Hoon, M. A. (2014) · Nature Neuroscience · doi:10.1038/nn.3619 · Cited by 338
Basophils and allergic inflammation
Siracusa, M. C., Kim, B. S., Spergel, J. M., & Artis, D. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.046 · Cited by 313
Zhao, Z.-T., Ji, C.-M., Yu, W.-J., Meng, L., Hawro, T., Wei, J.-F., & Maurer, M. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1342 · Cited by 303
Self-citationMechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Kaplan, A. P., Giménez-Arnau, A. M., & Saini, S. S. (2017) · Allergy · doi:10.1111/all.13083 · Cited by 293
Self-citationMetz, M., Ohanyan, T., Church, M. K., & Maurer, M. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.08.011 · Cited by 274
Self-citationMaurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.032 · Cited by 270
Self-citationAsthma phenotypes and IgE responses
Froidure, A., Mouthuy, J., Durham, S. R., Chanez, P., Sibille, Y., & Pilette, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.01824-2014 · Cited by 267
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02141 · Cited by 241
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
The ingenious mast cell: contemporary insights into mast cell behavior and function
Dahlin, J. S., Maurer, M., Metcalfe, D. D., Pejler, G., Sagi‐Eisenberg, R., & Nilsson, G. (2022) · Allergy · doi:10.1111/all.14881 · Cited by 147
Self-citationMaurer, M., Staubach, P., Raap, U., Richter‐Huhn, G., Bauer, A., Ruëff, F., Jakob, T., Yazdi, A. S., Mahler, V., Wagner, N., et al. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12900 · Cited by 131
Self-citationChan, S., Cornelius, V., Cro, S., Harper, J. I., & Lack, G. (2020) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2019.4476 · Cited by 130
Staubach, P., Metz, M., Chapman‐Rothe, N., Sieder, C., Bräutigam, M., Canvin, J., & Maurer, M. (2016) · Allergy · doi:10.1111/all.12870 · Cited by 130
“Previous studies have shown the positive effect of omalizumab in reducing the number of angioedema-burdened days, measured as ‘angioedema-free days’ (10, 11).”
ResultSelf-citationPruritus in allergy and immunology
Yang, T.-L. B., & Kim, B. S. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.016 · Cited by 112
Broesby‐Olsen, S., Vestergaard, H., Mortz, C. G., Jensen, B., Havelund, T., Hermann, A. P., Siebenhaar, F., Møller, M. B., Kristensen, T. K., Bindslev‐Jensen, C., et al. (2018) · Allergy · doi:10.1111/all.13237 · Cited by 112
“This differs from experiences in chronic spontaneous urticaria (CSU) where the response to omalizumab is rather quick, and disease control reached within 1-3 injections in the majority of patients.(7) However, also in CSU, around 10% of patients obtain a slower response to therapy, and it is possible that omalizumab a…”
BackgroundNew and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Antihistamine‐resistant chronic spontaneous urticaria: 1‐year data from the AWARE study
Maurer, M., Raap, U., Staubach, P., Richter‐Huhn, G., Bauer, A., Oppel, E. M., Hillen, U., Baeumer, D., Reinhardt, M., & Chapman‐Rothe, N. (2019) · Clinical & Experimental Allergy · doi:10.1111/cea.13309 · Cited by 74
Self-citationOmalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS
Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.039 · Cited by 70
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab
Zink, A., Gensbaur, A., Zirbs, M., Seifert, F., Suarez, I., Mourantchanian, V, Weidinger, S., Mempel, M., Ring, J., & Ollert, M. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2165 · Cited by 67
Pros and Cons of Clinical Basophil Testing (BAT)
Hoffmann, H. J., Knol, E. F., Ferrer, M., Mayorga, L., Sabato, V., Santos, A. F., Eberlein, B., Nopp, A., & MacGlashan, D. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0633-6 · Cited by 50
Yuan, W., Hu, S., Li, M., Yang, L., Liu, L., Zheng, M., Guo, Z., Song, Z., Zhang, C., Diao, Q., et al. (2022) · Dermatologic Therapy · doi:10.1111/dth.15303 · Cited by 36
A Patient Charter for Chronic Urticaria
Maurer, M., Albuquerque, M., Boursiquot, J.-N., Dery, E., Giménez-Arnau, A., Godse, K., Guitiérrez, G., Kanani, A., Lacuesta, G., McCarthy, J., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02724-6 · Cited by 10
Self-citation
Metadata
- Authors
- Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., & Casale, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-03-07
- Volume
- 368
- Issue
- 10
- Pages
- 924-935
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2121663010
- Cited by
- 1,105
- References
- 25
- FWCI
- 72.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.